about
Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptorSolution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound statesCrystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptorDe-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signallingThe crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkCStructural and functional analysis of the ligand specificity of the HtrA2/Omi PDZ domainStructural and functional analysis of the PDZ domains of human HtrA1 and HtrA3Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF bindingInhibition of Wnt signaling by Dishevelled PDZ peptidesVariants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding siteAntibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in miceThe development of peptide-based tools for the analysis of angiogenesisInhibiting Alternative Pathway Complement Activation by Targeting the Factor D ExositeStructural determinants of MALT1 protease activityStructure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clusteringDiscovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactionsCis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinaseDesign of synthetic autonomous VH domain libraries and structural analysis of a VH domain bound to vascular endothelial growth factorMechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersDiscovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1Crystal structure of the complex between VEGF and a receptor-blocking peptideA structure-based database of antibody variable domain diversity.Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.Convergent and divergent ligand specificity among PDZ domains of the LAP and zonula occludens (ZO) families.Improving therapeutic efficacy of a complement receptor by structure-based affinity maturation.Ligand-binding sites in Ig-like domains of receptor tyrosine kinases.Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodiesOn the edge of validation--cancer protease fibroblast activation protein.A role of macrophage complement receptor CRIg in immune clearance and inflammation.Targeted inhibition of the COP9 signalosome for treatment of cancerAla657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.Structure of neprilysin in complex with the active metabolite of sacubitril.Allosteric inhibition of protein tyrosine phosphatase 1B.The discovery of first-in-class drugs: origins and evolution.Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.Cryo-EM in drug discovery: achievements, limitations and prospectsSmall-molecule factor B inhibitor for the treatment of complement-mediated diseasesVariations on ligand-receptor complexes
P50
Q22010543-FC21B3DE-43AA-4F25-9417-FE5B425D6B77Q22010734-7D1A375C-ADDF-4087-8C46-E0DFDD5E939DQ24294589-B9EBA441-B575-4C0B-8AAD-897A0D678C15Q24299573-04151208-3122-4C75-B373-0C6210171F07Q24302171-441902A1-C46D-48BE-9C15-467AEA5F2C4AQ27618870-9A8415F8-4398-4989-AEB2-4ECBF093785CQ27646892-729D9E4B-8D0A-4BF2-BCC9-A866F59FA2B2Q27648904-D379963B-F8F8-49EF-880A-E80D38D6104FQ27648978-12F51331-B308-4C0E-8088-792C9D5A3B4FQ27653983-C94EA020-7372-429E-8030-CBC5961395FDQ27654214-6F2A978D-5CC7-44F6-B6C0-401A28BBE8E3Q27654979-742C2B4C-2EA4-43EE-9F3B-208173C2A4EDQ27671232-6D6EFA06-107A-404B-AA4F-79727A5FE6BCQ27677455-1F801C61-8722-402B-9F60-294DD7153ADCQ27677492-B122CD68-5747-4C6D-A4CC-7A4A9743DD43Q27678057-313BD12E-AED2-4F59-AFD6-B6331DD64AB5Q27678556-409AC13C-5C81-4457-A27A-F8CFF2414F3BQ27683636-189D31C3-E4EC-4E3F-9EA0-2A24A4204FC0Q27684200-7353190E-394D-48E1-AA0E-3BCDF551FD7CQ27685364-A3C50880-A9A6-432E-80AA-2DD61F117840Q27696281-57EE5DF9-D9BA-4623-A605-1141E715DAB9Q27700874-0067D266-B88E-4282-A448-EBF16BBB158DQ27766750-0366D75C-DF7C-4D65-9229-6585CBCFF710Q31159542-EB3A9E77-44CF-44CD-8A25-F21494C1674CQ33230191-CF227B54-90BA-4FCB-9B53-1F19DC8C25A9Q33245309-73E31F5B-6F7B-4371-8179-63D0C2BCCFACQ33510862-BF380353-E346-4E3F-92CA-EE651744824CQ34011682-6D5FF7A9-8FF9-4C41-AD41-7E383FD0918EQ35652113-514EDBE3-2C4C-4B7D-9B0E-F3628669504EQ37185297-3D3C3AD5-43E5-4E46-AC73-00F2776BEC12Q37254633-081225DF-6353-4929-8820-B2245AF653E7Q37364323-AB396D7F-7EF7-4E81-B85D-A831D2608503Q40155153-EB125C45-E0F7-4108-B90E-0F318E4DB2D6Q42712375-2ADA9DA3-7F41-490C-A89E-76F230605ACDQ44982496-E5448C80-9128-41C8-A599-4010EE12B666Q48070614-E1AEDA33-0418-4EC2-B805-1902D5FE2AE9Q50056675-E04BFA78-72EE-400D-8EE0-0BC078EBC81AQ57178721-72902F17-4196-497D-8135-857B01A80477Q64105051-F73540F4-BD30-4FBC-BE64-E513EFF82060Q73956062-52FCF876-E54E-4B36-A1B4-0023279DD98C
P50
description
researcher ORCID ID = 0000-0002-4092-9880
@en
wetenschapper
@nl
name
Christian Wiesmann
@ast
Christian Wiesmann
@en
Christian Wiesmann
@es
Christian Wiesmann
@nl
type
label
Christian Wiesmann
@ast
Christian Wiesmann
@en
Christian Wiesmann
@es
Christian Wiesmann
@nl
prefLabel
Christian Wiesmann
@ast
Christian Wiesmann
@en
Christian Wiesmann
@es
Christian Wiesmann
@nl
P1153
35596883700
P21
P31
P496
0000-0002-4092-9880